MedPath

Bimatoprost

Generic Name
Bimatoprost
Brand Names
Durysta, Latisse, Lumigan
Drug Type
Small Molecule
Chemical Formula
C25H37NO4
CAS Number
155206-00-1
Unique Ingredient Identifier
QXS94885MZ
Background

Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.

Indication

Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.

Bimatoprost is also indicated to treat eyelash hypotrichosis.

Associated Conditions
Hypotrichosis of the eyelashes, Increased Intra Ocular Pressure (IOP)
Clinical Trials
Related News

SpyGlass Pharma Appoints Veteran Pharmaceutical Executive as Chief R&D Officer to Advance Intraocular Drug Delivery Platform

• SpyGlass Pharma has appointed Chetan Pujara, Ph.D., as Chief Research & Development Officer to lead the company's proprietary intraocular drug delivery platform into Phase 3 trials. • Dr. Pujara brings over 20 years of leadership experience in pharmaceutical development and has contributed to market-leading products including Ozurdex®, Durysta™, and other ophthalmic therapies. • The SpyGlass Drug Delivery Platform with bimatoprost is designed to deliver three years of sustained medication release for glaucoma patients, with potential applications in additional ophthalmic conditions.

MediPrint's Weekly Glaucoma Contact Lens Shows Promise in Phase 2b Trial, Patents Secured Through 2043

• MediPrint Ophthalmics' LL-BMT1, a 3D-printed drug-eluting contact lens for glaucoma treatment, demonstrated comparable efficacy to daily bimatoprost eye drops in Phase 2b trial. • The company secured US Patent No. 12,178,904 for prostaglandin delivery via contact lenses, expanding their portfolio to 29 granted patents with protection through 2043. • MediPrint plans FDA discussions in 2025 for Phase 3 trials, potentially advancing a once-weekly treatment option that could improve patient compliance in glaucoma care.

Ocular Hypertension: Over 60 Companies Advance Clinical Trial Pipeline

• The ocular hypertension market is expanding due to increased prevalence of conditions affecting aqueous humor outflow, leading to elevated intraocular pressure (IOP). • Advancements like sustained-release implants and micro-dosing technologies are enhancing patient compliance and improving outcomes in ocular hypertension treatment. • Enhanced imaging techniques, such as optical coherence tomography (OCT), facilitate early diagnosis and intervention, contributing to the growth of the ocular hypertension market. • Over 60 companies are actively developing more than 70 pipeline drugs for ocular hypertension, signaling robust innovation and future growth potential in the domain.

Otulfi (Ustekinumab) Biosimilar Gains Regulatory Approvals in Canada and the UK for Inflammatory Diseases

• Health Canada approved Otulfi, a ustekinumab biosimilar, for subcutaneous and intravenous use in treating Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis. • The UK's MHRA also approved Otulfi for the same indications, following approvals in the US and Europe, expanding treatment options for inflammatory diseases. • Otulfi, developed by Formycon and commercialized by Fresenius Kabi, targets interleukin-12 and interleukin-23, offering a cost-effective alternative to Stelara. • These approvals underscore the commitment to increasing access to biosimilars, potentially reducing healthcare costs and improving patient access to essential medicines.

EMA Recommends Approvals for Novel Therapies Targeting Cancer, Hemophilia, and Neurological Disorders

• The EMA's CHMP recommended ten new medicines for approval, including Alhemo for hemophilia and Wainzua for hereditary transthyretin-mediated amyloidosis. • Positive opinions were adopted for two influenza vaccines, Fluad and Flucelvax, and for Siiltibcy, a diagnostic for Mycobacterium tuberculosis infection. • CHMP recommended extensions of indication for twelve already authorized medicines, expanding treatment options for various conditions. • The committee elected Bruno Sepodes as its new chair and Outi Mäki-Ikola as its new vice-chair, effective September and October 2024, respectively.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy